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The Factor VII Zymogen Structure
Reveals Reregistration of  Strands during Activation
Fibrinogen to Fibrin, activates platelets, and also initi-
ates an anticoagulatory process when it combines with
Thrombomodulin and activates Protein C. Activated
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1 Department of Protein Engineering and Protein C degrades key cascade components and termi-
nates Fibrin deposition [1]. Full enzymatic activity of2 Department of Cardiovascular Research
Genentech, Inc. FVIIa arises in a complex with the cell bound cofactor,
Tissue Factor (TF). The TF/FVIIa complex activates theSouth San Francisco
California biologically important substrates factor X (FX), factor
IX (FIX), and FVII. Binding of the zymogen FVII to TF
increases the rate of its conversion to FVIIa [2]. While
many enzymes are capable of converting FVII to FVIIa,Summary
FXa is probably the most important one in vivo [3]. In
addition to a protease domain with Trypsin homologyBackground: Coagulation factor VIIa (FVIIa) contains a
at its C terminus (“heavy chain”), FVII also has threeTrypsin-like serine protease domain and initiates the
N-terminal domains, collectively called the “light chain.”cascade of proteolytic events leading to Thrombin acti-
The first of these is rich in -carboxyglutamic acid resi-vation and blood clot formation. Vascular injury allows
dues (Gla) and promotes association with cellular mem-formation of the complex between circulating FVIIa and
branes. The Gla domain is followed by two epidermalits cell surface bound obligate cofactor, Tissue Factor
growth factor-like (EGF) domains, the second of which(TF). Circulating FVIIa is nominally activated but retains
is closely associated with the protease domain. In TF/zymogen-like character and requires TF in order to com-
FVIIa, the Gla and EGF1 domains have the most energet-plete the zymogen-to-enzyme transition. The manner in
ically important TF interactions, although the EGF2 andwhich TF exerts this effect is unclear. The structure of
the protease domains also contact TF [4, 5]. The conver-TF/FVIIa is known. Knowledge of the zymogen structure
sion from FVII to FVIIa involves a proteolytic cleavageis helpful for understanding the activation transition in
between the EGF2 and protease domains.this system.
There is considerable interest in the exact nature of
changes in FVII during its conversion from the zymogenResults: The 2 A˚ resolution crystal structure of a zymo-
to a fully active enzyme in the TF/FVIIa complex. Thegen form of FVII comprising the EGF2 and protease
activation of gastric serine proteases Trypsin and Chy-domains is revealed in a complex with the exosite bind-
motrypsin is structurally well characterized [6]. Cleavageing inhibitory peptide A-183 and a vacant active site.
of a single peptide bond releases a pro-peptide, gener-The activation domain, which includes the N terminus,
ates the mature N-terminal residue (Ile16 in FVIIa, ac-differs in ways beyond those that are expected for zymo-
cording to the Chymotrypsinogen numbering conven-gens in the Trypsin family. There are large differences
tion), and promotes conformational changes that createin the TF binding region. An unprecedented 3 residue
the active enzyme. This general scheme has also beenshift in registration between  strands B2 and A2 in
seen in crystal structures of Prethrombin2 [7, 8], Plas-the C-terminal  barrel and hydrogen bonds involving
minogen [9–12], and Complement Factor D [13]. TheGlu154 provide new insight into conformational changes
structural changes arise in a contiguous collection ofaccompanying zymogen activation, TF binding, and en-
four peptide segments collectively termed the activationzymatic competence.
domain [14]. Principal among these peptide segments
is the new N terminus itself, which becomes buried withConclusions: TF-mediated allosteric control of the ac-
its nonpolar side chain in a hydrophobic environmenttivity of FVIIa can be rationalized. The reregistering 
and its charged -amino nitrogen atom compensatedstrand connects the TF binding region and the N-termi-
by a salt bridge to a key aspartic acid side chain from thenal region. The zymogen registration allows H bonds
catalytic active site. Three associated loop segmentsthat prevent the N terminus from attaining a key salt
undergo changes that create the substrate binding cleft.bridge with the active site. TF binding may influence an
For the structurally characterized zymogen/enzymeequilibrium by selecting the enzymatically competent
pairs, and for a large number of other homologous pro-registration.
teins, this activation scenario provides full enzymatic
competence. For FVIIa, however, the “activated” form
Introduction exhibits poor amidolytic activity (small substrate mim-
ics), is essentially devoid of proteolytic activity (protein
Coagulation factor VII (FVII) initiates a cascade that substrates), and attains full activity only when associ-
stems blood loss through the generation of a Fibrin clot. ated with TF. The low activity of FVIIa has been ascribed
Each step in the cascade involves the conversion of a to an incomplete conversion of its activation domain
serine protease zymogen into its active form until Pro- from the zymogen form to the enzyme form [5, 15, 16]
thrombin is converted into Thrombin. Thrombin cleaves
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Table 1. Structure Statistics for A-183/rF7
Data Collection and Reduction
Resolution (A˚) Nmeas1 Nref2 Complete3 I/ Rmerge4 Rwork5 Rfree6
35.0–4.31 13,883 3,554 99.5 22 0.033 0.204 0.243
4.31–3.42 14,075 3,423 100 23 0.045 0.175 0.179
3.42–2.99 14,044 3,390 99.9 22 0.047 0.186 0.213
2.99–2.71 13,853 3,336 100 18 0.067 0.193 0.226
2.71–2.52 13,788 3,350 99.9 14 0.102 0.212 0.244
2.52–2.37 13,692 3,326 100 10 0.134 0.211 0.228
2.37–2.25 13,553 3,319 100 8.5 0.246 0.229 0.251
2.25–2.15 13,415 3,324 99.8 6.4 0.255 0.241 0.235
2.15–2.07 13,172 3,284 100 5.0 0.364 0.265 0.316
2.07–2.00 12,516 3,318 99.7 3.4 0.422 0.318 0.341
35.0–2.00 135,991 33,624 99.9 9.7 0.062 0.204 0.227
Refinement Statistics
Contents of Model rms Deviations
Residues Atoms7 Waters Ca2 SO24 Bonds Angles B factors (Main) (Side)
313 2,678 (41) 199 0 1 0.007 A˚ 1.5 3.0 A˚2 4.5 A˚2
1 Nmeas is the total number of observations measured.
2 Nref is the number of unique reflections measured at least once.
3 Complete is the percentage of possible reflections actually measured at least once. The number in parentheses is for the outermost tenth
of the data.
4 Rmerge  	||I|  |
I||/	|
I|, where I is the intensity of a single observation and 
I the average intensity for symmetry equivalent
observations.
5 Rwork  	|Fo  Fc|/	|Fo|, where Fo and Fc are observed and calculated structure factor amplitudes, respectively.
6 Rfree  Rwork for 698 reflections sequestered from refinement.
7 Number in parentheses is the number of atoms assigned zero occupancy.
because, for instance, the protease domain’s N-terminal a peptide, called A-183, which was recently discovered
by the use of phage display and selection for binding-amino nitrogen is more susceptible to chemical modi-
fication in the absence of TF than in its presence [17]. to TF/FVIIa. Peptide A-183 is a potent inhibitor of TF/
FVIIa that binds to a new exosite on the protease domainCrystallographic analyses of the various “forms” of
FVII are confounded by the interplay among allosteric [25, 26], which is distinct from that of another recently
described class of peptide exosite inhibitors [21]. Duringinfluences exerted at three sites on the protease domain
[18]. The first of these sites is the TF binding region, the refinement of the A-183/rF7 complex, we ascertained
that the crystals contained the zymogen form of rF7.second is the active site binding cleft, and the third is a
region including the protease domain N terminus, which Because Trypsin-like proteins comprise two  barrel
subdomains, we judged the analyses of the A-183 exo-contacts macromolecular substrates. The crystal struc-
ture of TF/FVIIa with a covalent inhibitor in the active site, located in the first  barrel, and the activation do-
main, located in the second  barrel, to be both distinctsite revealed details of the interface between TF and
FVIIa, including TF contacts on the catalytic domain [4]. and separable. Therefore, we have segregated our re-
porting of these two aspects, both derived from a singleIt also showed that the TF contact on FVIIa does not
include the protease domain’s N terminus, so that the X-ray structure, accordingly. In a separate report, we
present the molecular details of the interaction betweeninfluence of TF on the chemical modification of the N
terminus must arise from an allosteric effect. Additional A-183 and its exosite on rF7 [26]. In this report, we
describe the zymogen form of rF7 and characterize anallosteric crosstalk is observed between the active site
substrate binding cleft and the TF contact region [15, expanded activation domain including an unprece-
dented new registration between two  strands. Differ-19, 20] and between the binding cleft and the protease
domain N terminus [15]. Recent X-ray structures of FVIIa ences in the TF interaction region are large and suggest
how TF binding may induce allosteric effects, includinglacking the TF component [21–23] have shown protease
domains similar to those found with TF [4, 24], with a the reorganization of the macromolecular substrate exo-
site and the insertion of Ile16 into its hydrophobic pocketburied N terminus and an almost unchanged TF contact
region. However, because these structures also have a with concomitant formation of the critical salt bridge
with Asp194.substrate mimic in their active site binding clefts, the
allosteric connections to the TF contact site and the N
terminus may condition them to look like the TF/FVIIa form. Results and Discussion
The notion of incomplete zymogen conversion directs
attention to the zymogen itself. Our structural interest We began study of these crystals expecting them to
contain peptide A-183 and the activated form of thein this area led us to produce a simplified version of FVII
that retains only the EGF2 and catalytic domains (called shortened FVII construct rF7 (EGF2 plus protease do-
mains). The molecular replacement search model com-rF7). We were able to crystallize rF7 in the presence of
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Figure 1. Electron Density Indicates Differences with Prior FVIIa
Structures
Electron density maps (2Fo-Fc, 1.0 rmsd, blue; Fo-Fc, 3.0 rmsd, red)
indicating the 3 residue shift of  strand B2.
(a) Incorrect registration.
(b) Corrected registration from the final model. Maps were calculated
with phases from the incorrect registration (Rwork  26.2%, Rfree 
28.2%), with the Arg162 side chain assigned zero occupancy.
posed of these parts from the TF/FVIIa structure permit-
ted a straightforward solution. However, early in the
refinement, certain features in the electron density maps
led us to suspect that the crystals contained the zymo-
Figure 2. Metrical Comparison with FVIIagen instead of the enzyme. Confirmation of the zymogen
(a) Refined thermal factors (B values) for C atoms from the proteasewas made by the single N-terminal amino acid sequence
domain of A-183/rF7 as a function of those of the primary sequence.of the single protein band developed in a reducing SDS-
(b) Distance between corresponding C atoms after superposition-
PAGE gel run with harvested crystals. If the activating ing of A-183/rF7 and TF/FVIIa [4] as a function of primary sequence.
cleavage between the EGF2 and protease domains had Residues used for superpositioning (upward-pointing triangle,
occurred, then two SDS bands and two N-terminal se- cyan), prototype activation domain residues from Trypsin [14]
(downward-pointing triangle, red), residues contacted by peptidequences would have been found. After the presence of
A-183 (circle, green), residues in the first  barrel domain (– – –),the zymogen became unambiguous, we rebuilt a signifi-
residues in the second  barrel domain (- - -). Residues 73–75 andcant fraction of the model. In this fraction, correspon-
142–150 are disordered and not included in the model. In the first
dence between model and electron density was poor
 barrel, there are some differences associated with the presence
(Figure 1, Table 1). The very significant differences be- of peptide A-183, but overall the first  barrels are far more similar
tween the rF7 protease domain and prior FVIIa struc- than the second  barrels. Superposition of all corresponding C
atoms yields an rms deviation of 1.1 A˚ for the first  barrel andtures are evident in Figure 2a, which recapitulates the
5.2 A˚ for the second  barrel. Contacts between crystallographicanalysis of Trypsin/Trypsinogen by Huber and Bode [14]
symmetry-related molecules may influence the position of residuesand their characterization of the prototypical activation
184–193.
domain. The significant differences between A-183/rF7
and prior TF/FVIIa and FVIIa structures are mostly found
within the second  barrel, which contains the activation
the Glu70-Glu80 loop is not occupied, and part of thedomain (Figure 3). Differences within the first  barrel
loop is disordered. Residues 142–150 are also too poorlyare clearly associated with the presence of A-183 [26].
ordered to be traced. The poor ordering in the calciumGiven these considerations, we argue that the structure
binding loop may derive from the disruption of H bondsof each  barrel is largely independent of the other and
with neighboring residues, which are present in TF/FVIIa.that their analyses are separable. Here we concentrate
The disruption is caused by changes in the Cys22-Cys27on the second  barrel.
loop (see below). The C atoms of activation domain
loops 184–193 and 215–224 shift by up to 12 A˚ (Figure
2a). These two loops have high thermal factors (FigureThe Canonical Activation Domain
Striking differences in the second  barrel are found in 2b) and were fit into feeble electron density. Despite the
presence of 5 mM benzamidine in the crystallizationcomparison to prior FVIIa structures ([4, 21–24]; Figures
2a and 3). Despite the presence of 5 mM Ca2 in the medium, the S1 substrate pocket is not occupied. In-
deed, the S1 pocket does not exist due to shifts incrystallization medium, the high-affinity calcium site in
Structure
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Figure 3. Superposed zymogen and Enzyme
Stereoview of protease domains from A-183/rF7 (white) and TF/FVIIa (red). A-183 is in green. Some changes associated with binding of A-183 are
apparent, but the first  barrels (upper left) are largely the same. The most significant differences are in the second  barrel in the lower right.
The catalytic triad (Asp102, His57, and Ser195) and selected residues are labeled in black. When labeled residues from the two protease
domains are widely separated, red labels are used for TF/FVIIa. Activation domain loops are highlighted in blue (184a–197) or yellow (214–225).
Another activation domain loop (142–152) is disordered in A-183/rF7 but is present for TF/FVIIa. Spheres represent the C atom of Asp189
from each structure. The side chain of Glu154 from A-183/rF7 shows H bonding to main-chain nitrogen atoms (dark blue spheres) of residues
21 and 22. The corresponding nitrogen atoms of TF/FVIIa are in light blue.
relevant sections of the protein. For example, Asp189, main-chain H bonds with residues 20 and 22. In the
present structure, residues 151–168 are shifted by 3which is at the bottom of the S1 pocket in TF/FVIIa, is
shifted by 12 A˚ in rF7. amino acid residues toward the C terminus relative to
TF/FVIIa (Figure 5). Thus, the loop preceding  strandThe most conspicuous differences, however, occur
in the N-terminal residues 16–27 and the  strand B2 B2, despite not being resolved, must be 3 amino acids
shorter than in prior structures. The three residues(residues 153–162 [12]). Residues 16–19 are too poorly
ordered to be traced, as are residues at the end of the added at the C-terminal end of this strand are largely
taken up before Cys168 by addition to the N-terminalEGF2 domain to which they are still connected in the
zymogen. The poor ordering of residues 16–19 is signifi- end of the  helix 1. The position of  strand A2 does
not differ, and the pattern of inter- strand main-chaincant because of the key structural role played by a salt
bridge between the -amino nitrogen of Ile16 and the
side chain of Asp194. This salt bridge is critical in the
formation of a competent catalytic site in the active
enzyme. We are able to fit residues starting at Lys20,
but the main-chain trace of the loop between Cys22
and Cys27 is approximately reversed relative to TF/FVIIa
(Figure 4). As a result, Lys20 is farther away from Asp194
and closer to Lys143L, to which it is connected via 13
intervening amino acids. Not unexpectedly, these 13
residues are completely disordered in the present crys-
tal. Of these 13 residues, the 9 that are formally part of
the light chain after activation are also disordered in
all prior structures of FVIIa. Additionally, an inherent
flexibility and solvent exposure for this segment in FVII
is consistent with the requirement that it be available to
another enzyme’s active site for the activating cleavage
reaction to occur.
Figure 4. Differences in the N-Terminal RegionReregistered  Strand
A-183/rF7 is in white (protease domain) and blue (EGF2), TF/FVIIaA quite unanticipated feature in this structure is the 
is in red. The 13 amino acid connection between residues Lys20strand B2 (residues 153–162). This strand lies between
and Lys143L in A-183/rF7 is intact, based on N-terminal sequencingthe unresolved loop 142–150 and a short  helix (1)
of the single SDS/PAGE band, but it is too poorly ordered to be
that contains part of the TF binding region [5]. It shares traced. The backbone traces of residues 22–27 are in opposite direc-
main-chain-to-main-chain H bonds with  strand A2 tions. The poor ordering of residues 72–76 in A-183/rF7 is associated
with the new placement of the Glu26 side chain.(residues 134–140). In TF/FVIIa,  strand B2 also has
Factor VII Zymogen Structure
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Figure 6. H Bonds between Glu154 and Residues 21 and 22 in
A-183/rF7
With these H bonds, a newly created N-terminal Ile16 could not
reach into the insertion site and form a salt bridge with Asp194.
Changes in the Cys22-Cys27 loop cause Glu26 to displace residues
71 and 72 relative to TF/FVIIa, and prevent main-chain H bonds
between residues 71 and 73 and residues at the top of  strand B2.
This may explain residues 73–75 being unresolved.
chain-to-main-chain H bonds, the rF7  strand B2 has
H bonds from the side chain of Glu154 to the amide
nitrogen atoms of residues 21 and 22 (Figure 6) and
between the side chain of Asn159 and the side chains
of Ser136 and His199. In TF/FVIIa, all of the H bonds
beyond the eight main-chain-to-main-chain ones are
different. With the additional H bonds involving N-termi-
nal residues Ile16 and Val17, there are a greater number
in TF/FVIIa than in rF7 (15 versus 12).
The two structures also differ in the degree of solvent
exposure of nonpolar side chains from this region.
Leu155 displays 36% solvent accessibility in rF7 (rela-
tive to an extended Gly-Leu-Gly tripeptide), but it dis-
plays only 2% in TF/FVIIa. Leu158 undergoes a change
from 40% in rF7 to 4% accessibility in TF/FVIIa. Similar
differences apply to residues Pro161 and Leu163.
Figure 5. The Shifting  Strand Met156 is 51% solvent accessible in rF7 and 13% in
Comparison of  strand B2 in A-183/rF7 and TF/FVIIa. Worm and FVIIa. On the other hand, polar side chains tend to be
carbon atoms of A-183/rF7 are white. Worm and carbon atoms of more solvent accessible after registration to the TF/FVIIa
TF/FVIIa are pink. The pink worm draped across the top of B2
form. Asn159 has a low solvent accessibility in rF7 (16%)represents residues 16–23 of TF/FVIIa (these residues are either
relative to TF/FVIIa (38%) due to side-chain H bonds indisordered or in different positions in A-183/rF7). The close corre-
rF7 that are absent in TF/FVIIa (see above). For the samespondence of main-chain atoms allows H bonds with the companion
 strand A2 in both structures. The two different registrations of B2 reason, Glu154 has a lower accessibility in rF7 (19%)
share a similar pattern of polar and nonpolar side chains (except than in FVIIa (36%). Except for the H bonds lost by
Glu154/Val157), but solvent accessibility calculations show a more Glu154 and Asn159, the free energy associated with
favorable segregation into suitable environments in TF/FVIIa (pink).
these differences favors TF/FVIIa.Changes in the helical region preceding Cys168 disrupt the TF bind-
ing region of the protease domain in A-183/rF7.
TF Binding Region
Very significant differences exist for residues 160–176
(Figure 2a), including residues Met164, Asp167, andH bonds does not differ from earlier FVIIa structures,
but the residues complementing the  strand A2 are all Gln166, which are part of the TF binding region on the
protease domain ([4]; Figure 7). The differences at theshifted by 3 residues. In addition to the eight main-
Structure
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Figure 7. Stereoview of Tissue Factor Binding Region in A-183/rF7 and TF/FVIIa
TF is in blue with single-letter amino acid codes. A-183/rF7 is in white, and FVIIa is in red, both with three-letter amino acid codes. Underlined
are rF7 residues that are important contacts for TF in TF/FVIIa but differ significantly in the two structures. Purple side chains are from rF7
and would cause steric clashes with TF if unchanged. For reference, Asp194 C is labeled. Cystine Cys168–Cys182 is included from both
structures, and the comparison shows the opposite handedness.
start of this segment are associated with the extra three lent backbone or by proximity. The methionine loop pri-
mary sequence in FVII is longer than other structurallyamino acids from the preceding  strand, B2. At residue
Cys168, the correspondence with TF/FVIIa is sufficiently characterized zymogen/enzyme pairs, and this allows
greater conformational variability. Interestingly, recentrestored (the distance between corresponding Cys168
C atoms is 3.4 A˚) so that the disulfide bond still forms results demonstrate that the length of the FVII methio-
nine loop has functional relevance [28].with the almost unchanged Cys182. The differences in
the TF binding region not only withdraw residues that We have characterized the FVII zymogen structure by
using a shortened construct that lacks the Gla and EGF1are part of the TF interaction surface in TF/FVIIa but
also would prevent TF from assuming its normal position domains. Similar to how it is found in TF/FVIIa [29], intact
FVIIa is elongated in solution. This fact, in combinationrelative to the rest of the protease domain. In particular,
residues Arg162 and Leu163 would cause steric clashes with the small or zero difference between the affinities
of FVII and FVIIa for TF [17, 30–32], suggests that zymo-with TF residues Glu91/Pro92 and Tyr94, respectively,
if TF maintained the same structure displayed in the TF/ gen FVII is elongated even in the absence of TF. How-
ever, there is evidence of activation-dependent changeFVIIa complex ([4]; Figure 7). The structures of TF without
FVIIa [27] and in the TF/FVIIa complex are very similar, in the EGF1 domain [33], and this raises the possibility
that the missing domains influence the protease domainand this similarity makes large conformational changes
in TF due to interaction with FVII unlikely. in FVII. Definitive judgement on the validity of the trun-
cated structure must await structural information on full-
length FVII.The Activation Domain of FVII
In addition to the four elements composing the activa-
tion domain in Trypsin and Chymotrypsin, FVII also Important Role of Glu154 in the zymogen
The H bonds involving the Glu154 side chain may beshows differences in the short  helix 1 (containing
part of the TF binding region), the region centered on especially important in the activation process. With this
H bonding arrangement (Figure 6), a newly formed N-ter-170f (called the methionine loop), the  strand B2, the
Cys22-Cys27 loop, and the 70–78 loop. These additional minal -amino nitrogen atom cannot reach Asp194 and
establish the key salt bridge because residues 21 andelements are associated with specific features of the
FVII amino acid sequence and are coupled to each other 22 are held too far away (Figure 3). In the TF/FVIIa regis-
tration of B2, this restraint does not exist becauseand the four canonical elements either through the cova-
Factor VII Zymogen Structure
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Glu154 is in the 142–154 loop and Val157 occupies its A functional kinship between zymogen FVII and FVIIa
without TF has been recognized because the first isformer position. The glutamate in FVII is unusual for
position 154 among mammalian Trypsin-like serine pro- inactive and the second is poorly active in comparison
to TF/FVIIa. To the extent that there is also a structuraltease sequences, although there is not strong conserva-
tion of any amino acid. The available murine, canine, kinship, the zymogen structure allows us to speculate
on how TF turns FVIIa into a true enzyme. Of the struc-bovine, rhesus monkey, and rabbit FVII sequences are
equivocal on the question of importance for this gluta- tural rearrangements for conversion to fully active TF/
FVIIa that are indicated by the zymogen structure, themate. The bovine FVII sequence has lysine, canine has
glutamine, and the others are glutamate. The possibility two that are unique to the FVII system are the remodeling
of the TF binding region and the reregistration of strandthat bovine zymogen FVII is fundamentally more en-
zyme-like by virtue of the Lys at 154 would help explain B2. Perhaps one or both of these is the origin of TF’s
allosteric influence on the active site and N terminus.the esterase activity ascribed to it [34]. Some related
proteins of known structure have glutamate at position In attempting to characterize FVIIa without TF by inter-
polation between the zymogen and TF/FVIIa, the ener-157, which is the position structurally analogous to
Glu154 in the rF7 zymogen [10, 12, 35, 36]. None of getic requirement of the transition is an important guide-
post. The energetic requirement of rF7 activation is notthese glutamate residues has H bonds like those in rF7.
A residue-specific, allosteric role for Glu154 has been known, nor is it known for authentic full-length FVII.
However, a useful surrogate measurement is available.described [37]. The Glu154 side-chain is required for
the transmission of an allosteric influence from the mac- Despite conflicting data on the difference in affinity of
TF for the zymogen and the enzyme (0- to 10-fold effectromolecular substrate exosite to the active site cleft.
The monoclonal antibody F3-3.2A recognizes an epitope on KD; [17, 30–32]), in no case is a large difference indi-
cated. Therefore, adoption of the TF/FVIIa-like TF bind-on the protease domain that includes the N-terminal
region, parts of the Ca2 binding loop (residues 70–80), ing region by the zymogen requires only about 1 kcal/
mol or less. Because FVIIa without TF possesses lowand Met156 on  strand B2 [38]. Residue Glu154 is not
part of its epitope in FVIIa [37], but its importance in but non-zero amidolytic activity, the activation barrier
to formation of the competent active site must not beFVII has not been reported. Interestingly, the antibody
binds more tightly to FVIIa without TF than to TF/FVIIa prohibitive. These data have been used to argue that
an equilibrium exists between relatively zymogen-like[38] (approximately 3-fold more tightly). This difference
apparently arises from the zymogen-like features pres- and relatively TF/FVIIa-like forms of FVIIa [15, 16] but
equally allow a similar equilibrium for the zymogen.ent in the FVII/FVIIa mixture against which it was raised
because it displays 2-fold tighter binding to FVII than In contrast, reregistration of  strand B2 would seem
to require a considerable activation energy. The detailsto FVIIa [38]. The antibody also reduces the amidolytic
activity of TF/FVIIa through an allosteric effect, probably of the molecular process of transition from one registra-
tion to the other is open to speculation. To our knowl-the induction of, or preference for, zymogen-like fea-
tures. The allosteric reduction of amidolytic activity is edge, it is unprecedented. However, the FVII sequence
is particularly amenable to the 3 residue registrationalmost eliminated when Glu154 is mutated to alanine
[37], and this finding is consistent with the Glu154 side shift in that it contains a Leu-X-Val-Leu-X-Val tripeptide
repeat. The reregistration to a TF/FVIIa-like B2 permitschain being important for zymogen-like features recog-
nized by F3-3.2A. additional H bonds to form and results in a more favor-
able segregation of nonpolar and polar side chains (see
above). A roughly analogous conformational change oc-TF and “zymogenicity” in FVIIa
The formally activated FVIIa has a significant depen- curs during inhibition of proteases by serpins, including
the insertion of a newly formed  strand into an existingdence on TF for catalytic competence. For macromolec-
ular substrates, membrane bound or synthetic vesicle  sheet [43]. There is evidence that such an insertion is
reversible under mild conditions [44]. Based on thesebound TF enhances FVIIa function by about 105-fold
[39, 40]. Most of this dependence is explained by the observations, it is possible that reregistration occurs
under mild conditions as part of an equilibrium.membrane localization of TF/FVIIa and the macromolec-
ular substrate [41] and by substrate interactions directly Furthermore, we are attracted to a hypothesis that
the rearrangement of the TF binding region and the re-with TF [42]. However, there has been no explanation
for the purely allosteric increase (approximately 50-fold) registration of  strand B2 are linked, in the sense that
one requires the other. A competent TF binding regionremaining for small peptidyl substrates [19, 20]. A crystal
structure of FVIIa alone would help address this question seems likely to necessitate expulsion of the three “extra”
residues into  strand B2. Such a linkage is supportedbut is so far not available, partly because substrate-like
inhibitors are used for limiting unwanted autolysis during by the affinity loss between antibody F3-3.2A and FVIIa
when TF is present [38] because the antibody epitopepurification and crystallization. The presence in known
FVIIa structures of either a substrate mimic [21–23] or includes residues changed by the B2 reregistration.
However, F3-3.2A binds with equal affinity to zymogenboth a substrate mimic and TF [4, 24] has precluded
analysis of FVIIa with no allosteric influences. The distin- FVII with and without TF [38]. These results support the
hypothetical linkage in FVIIa but argue that it is absentguishing feature of the pertinent molecular species is
an N terminus that is accessible to carbamylation [17] in the zymogen. If the linkage is present in FVIIa, then
either the linkage is absent from the zymogen or F3-3.2Aand that therefore seems not to have established the
key Asp194 salt bridge, which conditions the active site accommodates the linkage-induced changes in some
energetically neutral manner that is not available withfor catalysis.
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FVIIa. Given the small size of the difference (approxi- Biological Implications
mately 3-fold) in affinity between the antibody and FVIIa
caused by TF, an energetically neutral accommodation of The importance of the balance between thrombosis and
hemostasis is suggested by its highly regulated naturethe zymogen seems possible. Alternatively, the TF binding
region on zymogen FVII could be different from the one and cofactor dependency. A major regulatory aspect of
the initial event in the extrinsic coagulation cascade canon FVIIa, and this or some other difference could in
some way preclude the linkage to B2 that seems present now be rationalized. It has long been known that the
serine protease coagulation factor VII/VIIa is present inin FVIIa. The resolution of this apparent discrepancy will
determine in which molecules (FVII and/or FVIIa) and by circulating blood but is largely inactive. Even the nomi-
nally activated FVIIa retains zymogen character, in con-which means (via linkage to B2 or not) TF binding exerts
an allosteric influence on the N-terminal region. According trast to related enzymes, such as Trypsin, in which acti-
vating cleavage(s) create a fully active enzyme. Uponto our linkage hypothesis, the Glu154→Ala FVIIa mutant
would have a tighter affinity for TF than would the wild exposure to the extravascular environment or to certain
membranes within atherosclerotic plaques, factor VIIatype, and it would have greater amidolytic activity than
the wild type. Shobe et al. have shown the first point to forms a complex with the cell-surface bound Tissue
Factor, and this combination proceeds to activatebe marginally true, but the second point seems not to
be the case [37]. downstream clotting factors as well as form more FVIIa.
The Tissue Factor part of this complex helps localize and
orient FVIIa and also guides substrates to productiveConclusion
The notion that TF selects an “active” form of FVIIa from interactions with the FVIIa active site. The exact nature
of an additional long-range allosteric effect transmittedan equilibrium with an “inactive” form is well established
[15, 16]. The zymogen structure adds new features to from the TF binding region to the FVIIa catalytic active
site has been subject to conjecture. The structure ofspeculation regarding the molecular details of this
scheme. As for related zymogens, FVII alone is not a zymogen FVII reported here includes an unprecedented
refolding relative to the TF bound form of FVIIa. A singlecatalyst because there is a poorly formed or absent
substrate binding cleft and no N-terminal -amino nitro- strand of secondary structure imbedded in the protein
structure must shift by 3 amino acid residues, or aboutgen to condition the active site via a salt bridge with
Asp194. For FVII, the energetically favored form of the 12 A˚, to attain the active enzyme structure. This shift
eliminates an impediment to full activity, and a key con-zymogen is probably the one characterized in this report.
Three caveats to this assertion should be kept in mind. formational change accompanying Trypsin family en-
zyme activation becomes possible. Therefore, we hy-Firstly, our structure was determined in complex with
the peptide A-183. However, the binding site for A-183 pothesize that the previously proposed equilibrium
between zymogen-like FVIIa and enzyme-like FVIIa isis far from most elements of FVII’s activation domain
and is in a different tertiary structural component of the shifted toward the enzyme-like species in TF/FVIIa be-
cause a well-formed TF binding region requires theprotease domain. Secondly, some structural details of
one of the activation domain loops may have been se- shifted strand, which, in turn, permits formation of the
fully competent active site.lected by intermolecular contacts within the crystal lat-
tice. Any structural effects of the intermolecular contacts
Experimental Proceduresare probably not significant in the following outline. Fi-
nally, our structure lacks the Gla and EGF1 domains,
Production of rF7 and A-183which are affected by events in the protease domain
A recombinant transfer vector, gp67ssFVII, consisting of the gp67
[33]. Without a structural explanation for this connection, signal sequence attached to FVII cDNA containing the EGF2 and
it is difficult to gauge how, or if, the absent domains protease domains only (residues Ile90L to Pro257) was constructed.
Similar simplifications of related enzymes are known [45]. The pro-would have altered our result.
tein of interest, rF7, is expressed as a gp67 signal peptide fusionThe key feature of this zymogen structure is a unique
protein under the control of the strong baculovirus polyhedrin pro-registration of  strand B2 that permits Glu154 H bonds
moter. To generate gp67ssFVII, we used a baculovirus transfer vec-with residues near the scissile Arg15-Ile16 peptide bond
tor, pAcGP67 (PharMingen, San Diego, California), and full-length
and, according to the linkage hypothesis, precludes TF human FVII cDNA as templates in a polymerase chain reaction (PCR)
binding. Because the energetic cost seems small, we to generate two products with the appropriate sequence. We per-
suggest there is also a significant minority of FVII mole- formed a second PCR reaction to anneal these two products and
to insert a SpeI restriction site at the 5 end and an EcoRI site atcules that have a reregistered B2, resulting in loss of
the 3 end. All PCR amplifications were for 35 cycles, with denatur-the Glu154 H bonds with residues 21 and 22 and a
ation for 1 min at 95C, annealing for 1 min at 55C, and extensioncompetent TF binding region. If TF binds to FVII, it would
at 72C for 1 min. The nucleotide sequences generated by PCR
select from this population. When the TF/FVII complex were confirmed by DNA sequencing with the dye terminator method
undergoes the activating cleavage reaction, the N termi- (PE Applied Biosystems, Foster City, California). The PCR product
nus–Asp194 salt bridge can be formed immediately, and was cloned into the SpeI and EcoRI sites of pAcGP67.
Spodoptera frugiperda insect cells, Sf9, were plated onto 6-wella fully competent enzyme results. Alternatively, when
dishes and transfected at 60%–70% confluence. The cells wereFVII is cleaved before association with TF, the equilib-
exposed to 1.5 g gp67ssFVII plasmid, 175 ng BaculoGoldTM linear-rium mixture would include a population in which H
ized DNA (PharMingen, San Diego, California), and 10 g Lipofectinbonds between Glu154 and residues 21 and 22 prevent
reagent (Life Technologies, Rockville Maryland) in serum-free Hink’s
the formation of the N terminus–Asp194 salt bridge. The TNM-FH supplemented GRACE’s insect media (JRH Biosciences,
catalytic activity of this equilibrium mixture would then Lenexa, Kansas) overnight at room temperature with rotation. After
incubation, the transfection medium was replaced with Hink’s sup-be low due to the presence of this incompetent form.
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plemented with 10% fetal bovine serum (Hyclone, Logan, Utah) for Department of Energy under contract number DE-AC03-76SF00098
at Lawrence Berkeley National Laboratory.4–5 days at 28C for production of the virus. The virus was amplified
2–3 times by the infection of Sf9 cells with cell supernatants in
monolayer cultures. The amplified viral supernatant was used for Received: March 21, 2001
the infection of High FiveTM cells (Invitrogen, San Diego, California Revised: June 8, 2001
and Expression Systems, Woodland, California), which express pro- Accepted: June 11, 2001
tein more efficiently. Briefly, High FiveTM cells in suspension cultures
were infected with the amplified virus, and expression was allowed
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